Cadrenal Therapeutics Inc (NASDAQ: CVKD) is a clinical-stage pharmaceutical company focused on developing drug candidates for unmet medical needs. The company generates no product revenue, operating entirely on external financing while advancing its pipeline toward clinical trials. As of December 31, 2025, Cadrenal had an accumulated deficit of approximately $39.0 million and recorded a net loss of approximately $13.2 million for the fiscal year ended December 31, 2025. The company's auditors issued a going-concern explanatory paragraph in connection with the FY2025 financial statements, citing substantial doubt about its ability to continue operations for the next twelve months. Cadrenal funds operations through equity issuances, including sales of common stock under an at-the-market facility and proceeds from warrant exercises. It relies entirely on third-party contract research organizations and clinical investigators to conduct its planned clinical trials. Reimbursement from Medicare, Medicaid, and private payers would be required for any future commercialized product.

Revenue model

No product revenue as of FY2025. Operations are funded through equity financing, including at-the-market common stock offerings and warrant-related proceeds. Future revenue, if any, would depend on regulatory approval and third-party payer reimbursement for commercialized drug candidates.

Products and services

Pre-commercial drug candidates in development, not yet in clinical trials as of the FY2025 10-K filing dated 2026-03-31. Specific product names are not identified in the available filing excerpts.

Customers and end markets

No commercial customers as of FY2025. Target end markets, if products reach commercialization, would include Medicare, Medicaid, managed care organizations, and private health insurers in the United States, as well as potential foreign markets.

Value-chain role

Drug developer operating upstream of commercialization. Cadrenal outsources clinical trial execution to contract research organizations, medical institutions, clinical investigators, and contract laboratories, while retaining regulatory responsibility for trial compliance under FDA Good Clinical Practice requirements.

Geographic exposure

Primary regulatory and operational focus is the United States, with reference to potential foreign markets for future commercialization. No specific international operations are described in the filing excerpts.

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: Johnson & Johnson